



### MLL3 Blocking Peptide (C-term)

Synthetic peptide Catalog # BP22080b

#### **Specification**

MLL3 Blocking Peptide (C-term) - Product Information

Primary Accession <u>Q8NEZ4</u>

MLL3 Blocking Peptide (C-term) - Additional Information

Gene ID 58508

#### **Other Names**

Histone-lysine N-methyltransferase 2C, Lysine N-methyltransferase 2C, 2.1.1.43, Homologous to ALR protein, Myeloid/lymphoid or mixed-lineage leukemia protein 3, KMT2C, HALR, KIAA1506, MLL3

#### Target/Specificity

The synthetic peptide sequence is selected from aa 3804-3818 of HUMAN KMT2C

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### **Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

MLL3 Blocking Peptide (C-term) - Protein Information

Name KMT2C

Synonyms HALR, KIAA1506, MLL3


**Function** 

# MLL3 Blocking Peptide (C-term) - Background

Histone methyltransferase. Methylates 'Lys-4' of histone H3. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. Central component of the MLL2/3 complex, a coactivator complex of nuclear receptors, involved in transcriptional coactivation. KMT2C/MLL3 may be a catalytic subunit of this complex. May be involved in leukemogenesis and developmental disorder.

### MLL3 Blocking Peptide (C-term) - References

Ruault M.,et al.Gene 284:73-81(2002). Tan Y.C.,et al.Cancer Detect. Prev. 25:454-469(2001). Hillier L.W.,et al.Nature 424:157-164(2003). Nagase T.,et al.DNA Res. 7:143-150(2000). Nakajima D.,et al.DNA Res. 9:99-106(2002).





Histone methyltransferase that methylates 'Lys-4' of histone H3 (PubMed:<a href="htt p://www.uniprot.org/citations/22266653" target="\_blank">22266653</a>). H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. Central component of the MLL2/3 complex, a coactivator complex of nuclear receptors, involved in transcriptional coactivation. KMT2C/MLL3 may be a catalytic subunit of this complex. May be involved in leukemogenesis and developmental disorder.

#### Cellular Location Nucleus.

#### **Tissue Location**

Highly expressed in testis and ovary, followed by brain and liver. Also expressed in placenta, peripherical blood, fetal thymus, heart, lung and kidney. Within brain, expression was highest in hippocampus, caudate nucleus, and substantia nigra. Not detected in skeletal muscle and fetal liver

## MLL3 Blocking Peptide (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides